Neutra Life Sciences Expands Clinical Research Network with New Family Medicine Partnership
Neutra Corp's subsidiary has expanded its clinical trial site network through a joint venture with MediNet Family Care Clinic, strengthening its position in community-based research for chronic conditions while enhancing investor communication.
Neutra Corp's wholly owned subsidiary, Neutra Life Sciences, has expanded its clinical research footprint by securing a new clinical trial site through a partnership with MediNet Family Care Clinic, which specializes in Internal Medicine and Family Medicine. This strategic move aligns with the company's ongoing mission to grow its site management organization and bring high-quality, community-based research opportunities to diverse patient populations.
The new Internal Medicine/Family Medicine site is located in a high-traffic area near the border of Sugar Land and Houston and is led by an experienced research team with a strong background in conducting clinical trials and delivering consistent, quality data. The site is fully equipped to support a wide range of protocol designs, including Phase II and III studies focused on chronic conditions such as hypertension, diabetes, hyperlipidemia, and other prevalent therapeutic areas.
This partnership represents another important step in Neutra Corp's long-term strategy to grow organically and provide sponsors and contract research organizations with efficient, responsive, and high-performing research sites. By expanding into Internal Medicine and Family Medicine, the company is furthering its ability to support diverse protocols while continuing to meet the highest standards of patient care and data integrity.
In a parallel development, Neutra Corp has engaged a dedicated Investor Relations Firm to strengthen communication and transparency with shareholders and the broader investment community. This strategic move underscores the company's commitment to building lasting investor confidence, enhancing market visibility, and providing timely, accurate insights into the company's growth, performance, and strategic direction.
Neutra Life Sciences continues to experience steady growth across multiple specialties, with plans to add additional therapeutic areas in the coming quarters. Each new site is carefully selected and supported to ensure optimal performance and alignment with sponsor and CRO expectations. With this expansion, Neutra Life Sciences is preparing to launch a new Diabetic Foot Ulcer trial at one of its brand-new sites in Sugar Land, Texas, demonstrating the practical application of its growing network capabilities.
The company maintains its corporate presence online at https://www.neutrainc.com, where investors can access additional information and performance data. This expansion into family medicine represents a significant step in making clinical research more accessible to diverse patient populations while strengthening the company's position in the competitive clinical research landscape.